To inquire about our available technologies, call our office (813) 745-6828
| Name & Description | Number |
|---|---|
| Liquid Biopsy: Saliva Based Liquid Biopsy Assay for Oropharyngeal Cancer | 23MA001N |
| Liquid Biopsy: Liquid Biopsy Based PCR Assay to Predict Drug Resistant in Prostate Cancer | 21MB071 |
| Liquid Biopsy: Liquid Biopsy Assay for Pan-cancer Early Detection Using Cell-free DNA Methylation | 21MB048 |
| Protein Diagnostic: Diagnostic to detect Leptomeningeal Disease | 20MB040N |
| Molecular Imaging Agent: A Novel Fluorescence Molecular Imaging Agent for Intraoperative Margin Assessment in Breast Cancer | 20MA008N |
| Diagnostic for Predicting Response to Therapies in Multiple Myeloma | 19MB057 13MB048 - VIDEO |
| Companion Diagnostic to Predict Response to Immunotherapy Based on the Methylation Status | 19MB052T2 |
| Methylation Status Diagnostic: Diagnostic to Predict Response to Immunotherapy | 19MB052 - VIDEO |
| Genetic Signature: Gene Signature to Distinguish between Metastatic Urothelial Carcinoma and Squamous Cell Carcinoma (Primary Lung and Metastatic Head & Neck) | 17MB044 |
| Genetic Biomarker: PTEN Loss of Expression as a Biomarker Response to GGTI-2418 Treatment | 17MA025 |
| Molecular Imaging: Predicting Response to Adjuvant Ipilimumab Treatment in Melanoma Using a Novel Algorithm to Analyze Nitric Oxide Levels in Peripheral Blood Immune Cells | 17MA002N |
| miRNA Diagnostic: miRNA Signature for Non-invasive Early Detection of Malignancy in IPMN | 17MA001 |
| miRNA Diagnostic: MicroRNA Signature to Predict Progression of Barrett’s Esophagus to Esophageal Dysplasia or Adenocarcinoma | 16MB066 |
| Molecular Imaging Probe: Novel IDO1-Targeting Cancer Diagnostic PET Imaging Agent | 16MB044 |
| Protein Biomarker: Diagnostic to Determine which Low-Risk MDS Patients to Treat with Lenalidomide to Restore Sensitivity to Erythropoietin | 16MB042 |
| Protein Biomarker: Method for Measuring MRE11 in Muscle –Invasive Bladder Cancer to Predict Chemoradiation Response Using AQUA | 16MB041 |
| Genetic Signature: Gene Signature to Distinguish Lung Squamous Cell Carcinoma from Metastatic Head & Neck Squamous Cell Carcinoma | 16MB040 |
| Protein Biomarker: Diagnostic for Progression of MDS to AML Using PD-1 or PD-L1 Expression | 15MB065 |
| Molecular Imaging Probe: In vivo Positron Emission Tomography-Based Perfusion/Blood Pool Imaging Using Labeled Erythrocytes | 15MB042N |
| Diagnostic: S100A9 Serum Concentration Levels Predict Lenalidomide Response Duration | 15MA031N |
| Diagnostic: Intracellular S100A9 Alone or NLRP3 Inflammasome Activation as MDS Biomarkers | 15MA021N |
| Molecular Imaging: Monoacylated TLR2 Ligand Fluorescent Probe for Detecti | 15MA015 |
| Genetic Signature: Microarray-based Gene Expression Profiling to Predict Tumor Sensitivity to Radiotherapy | 14MA052N |
| miRNA Diagnostic: Blood Based microRNA Assay to Detect Malignant Intraductal Papillary Mucinous Neoplasms (IPMNs) | 13MB078 |
| Molecular Imaging: Novel Imaging Software Diagnostic to Determine Survival in Glioblastoma Multiforme | 13MB055 |
| Genetic Signature: Gene Signature Predicts Recurrence and Benefit From Adjuvant Chemotherapy in Colorectal Cancer | 13MA036 |
| Multiplex Diagnostic: in Multiple Myeloma Using Detection of Minimal Residual Disease RNA Sequencing and Mass Spectrometry | 13MA009 |
| Protein Diagnostic: Phosphorylated STAT3 Protein as a Novel Biomarker of Graft Versus Host Disease | 13MA002 |
| Molecular Imaging Probe: A Novel 18F Scaffold for Preparing Targeted PET Imaging Probess | 12MB104 |
| Genetic Signature: Gene Expression Signature to Determine the Benefit of Adjuvant Chemotherapy in Early Stage Non-Small Cell Lung Cancer | 12MA069 |
| Molecular Imaging Probe: Synthetic Fluorescent Probe for Improved Detection and Tumor Removal in Pancreatic Cancer Patients | 11MB064 |
| Molecular Imaging Probe: Surrogate Markers for Colon Adenoma and Adenocarcinoma | 11MA026N |
| Imaging: Digital Pathology Tool to Grade Breast Cancer Histological Images | 11MA022 |
| Protein Diagnostic: New Receptor Tyrosine Kinase Assay for Patient Treatment Selection Based on Protein-Protein Bindi | 11MA014 |
| Molecular Imaging Probe: Fluorescent and MRI Targeted Probes for the Melanocortin Receptor 1 on Melanomas, and Micelle Complexes for Drug Delivery | 10MB069N |
| Molecular Imaging Probe: Breast Cancer-Targeted Probe Set for Improved Detection of Lymph Node Metastases | 10MA024 |
